Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...

New Delhi, The Delhi High Court on Tuesday ordered auctioning of the Fortis trademark in connection with the ₹3,500 crore arbitral award passed in favour of Japanese pharma major Daiichi Sankyo ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...